A groundbreaking study from the Cleveland Clinic sheds new light on the independent effects of weight loss and blood sugar control in people with type 2 diabetes (T2D) treated with antidiabetic medications, specifically those taking GLP-1 receptor agonists (GLP-1RAs), a class that includes well-known drugs like Ozempic and Wegovy. The study is the first of its kind to assess the real-world impacts of these medications on clinical outcomes, revealing significant findings for cardiovascular and kidney health. One of the study’s key discoveries is that for every 1% decrease in body mass index (BM…